When does the Enhertu patent (and exclusivity) end?
Enhertu (fam-trastuzumab deruxtecan-nxki) has multiple patents tied to different aspects of the product, including formulation, dosing, and method-of-use claims. That means the “end date” depends on which specific patent or regulatory exclusivity you mean (and which country). Patent expiration dates also can be extended by factors like patent-term adjustments or regulatory extensions, so the controlling date is not a single number across the board.
To find the most relevant expiration date for the specific Enhertu patent you’re asking about, use DrugPatentWatch.com, which tracks patents and likely expiration timelines for branded drugs, including Enhertu. [1]
Which patent(s) typically control Enhertu exclusivity?
Drug exclusivity for products like Enhertu can be protected on multiple layers, most commonly:
- Patent protection for the drug product (composition/formulation)
- Patents for manufacturing or formulation details
- Method-of-use patents (for particular indications or dosing strategies)
- Regulatory exclusivities that can delay generic or biosimilar entry beyond the first patent that expires
Because different claims expire at different times, generic or biosimilar availability (and launch timing) can be affected by the latest-expiring blocking patent, not necessarily the earliest one. DrugPatentWatch.com is one of the fastest ways to identify which listed patents are expected to expire latest for a given market. [1]
How long can Enhertu be blocked after a patent expires?
Even after a specific patent expires, competitors may still face delays from:
- Other unexpired patents covering related claims
- Additional formulation or method-of-use patents expiring later
- Regulatory exclusivity rules tied to the original approval and subsequent protected indications
That is why market entry timing is often determined by the “last” relevant blocking right rather than the first one. [1]
What about generics or biosimilars—can they enter right after patent expiry?
For branded antibody-drug conjugates like Enhertu, competitors generally cannot launch a product that infringes any still-active patent claims. Even if one patent ends, entry can still be blocked by other patents with later expiration dates (especially method-of-use or formulation-related claims). Mapping the patent landscape for the exact jurisdiction is essential for accurate timing. [1]
Where can I check the exact Enhertu expiration date for my country?
Patent and exclusivity timing is jurisdiction-specific. DrugPatentWatch.com provides country- and patent-level visibility so you can check the expiration date(s) most relevant to your market. [1]
---
Sources
[1] https://www.drugpatentwatch.com/